Search results (1345)
« Back to PublicationsPATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
Mesa R. et al, (2015), HAEMATOLOGICA, 100, 336 - 337
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
Harrison C. et al, (2015), HAEMATOLOGICA, 100, 103 - 103
PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF MEGAKARYOCYTE-AND ERYTHROID-PRIMED MEGAKARYOCYTE-ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS
Psaila B. et al, (2015), HAEMATOLOGICA, 100, 97 - 97
The next steps in improving the outcomes of advanced ovarian cancer.
Openshaw MR. et al, (2015), Womens Health (Lond), 11, 355 - 367
A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
Thomas AL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
Olszanski AJ. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
Van Schaeybroeck S. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
Wainberg ZA. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.
Clark LL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012).
Sims MC. et al, (2015), Br J Haematol, 169, 452 - 455
Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.
Lord SR. et al, (2015), J Natl Cancer Inst Monogr, 2015, 81 - 86
Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
Borley J. et al, (2015), BJOG, 122, 843 - 849
B-cell depletion in immune thrombocytopenia.
Psaila B. and Cooper N., (2015), Lancet, 385, 1599 - 1601
Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs.
Iskander D. et al, (2015), Blood, 125, 2553 - 2557
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W. et al, (2015), Nat Commun, 6
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
Findlay JM. et al, (2015), Ann Oncol, 26, 624 - 644
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Suttle AB. et al, (2015), J Clin Pharmacol, 55, 392 - 400
Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: Preliminary results from the MAJIC Trial
Scherber R. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 81 - 81
Decision theory and cost-benefit analysis of re-staging oesophageal cancer after neoadjuvant chemotherapy with PET-CT rather than CT
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 41 - 41